Summary

Efficacy and safety data from the Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus: Assessment of Weekly Administration of LY2189265 in Diabetes-3 study [AWARD-3; NCT01126580] Phase 3, randomized, double-blind, parallel-arm, monotherapy study have revealed the superiority of once-weekly dulaglutide 0.75 or 1.5 mg compared with twice-daily metformin 1000 mg in controlling glycemia in type 2 diabetes.